drugset / Trial / NCT00193076

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

NCT00193076 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab. Additionally, recent clinical data suggest that the combination of gemcitabine with platinum is an active regimen in metastatic breast cancer. This study will test the combination of gemcitabine with carboplatin in patients with metastatic breast cancer. Patients with Her2/neu overexpression will be stratified to receive trastuzumab in addition to gemcitabine and carboplatin.

Timeline

Start
2003-11
Primary completion
2006-05
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 4 unknown Intravenous
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous

Indications